Literature DB >> 28680365

The approval of revised diagnostic criteria for DIC from the Japanese Society on Thrombosis and Hemostasis.

Hideo Wada1, Hoyu Takahashi2, Toshimasa Uchiyama3, Yutaka Eguchi4, Kohji Okamoto5, Kazuo Kawasugi6, Seiji Madoiwa7, Hidesaku Asakura8.   

Abstract

As proposed diagnostic criteria for DIC from the Japanese Society on Thrombosis and Hemostasis has been approved and revised, the contents and changes are informed.

Entities:  

Keywords:  DIC; Diagnostic criteria; Hemostatic molecular markers; JSTH

Year:  2017        PMID: 28680365      PMCID: PMC5496332          DOI: 10.1186/s12959-017-0142-4

Source DB:  PubMed          Journal:  Thromb J        ISSN: 1477-9560


Although disseminated intravascular coagulation (DIC) is a serious disease, there is no gold standard for its diagnosis, no single biomarker by which DIC can be clearly diagnosed, and no anticoagulants have been recommended for the treatment of DIC in worldwide [1]. We reviewed the diagnostic criteria for DIC including the newly proposed diagnostic criteria for DIC from the Japanese Society on Thrombosis and Hemostasis (JSTH) [2, 3]. Three diagnostic criteria for DIC have been established by the Japanese Ministry of Health and Welfare (JMHW) [4], the International Society of Thrombosis and Haemostasis [5] and the Japanese Association for Acute Medicine [6]. The three diagnostic criteria involve a scoring system based on the results of global coagulation tests (GCTs) such as the platelet count, prothrombin time (PT), fibrinogen and fibrin-related markers. Thus, there were no significant differences in the usefulness among three different diagnostic criteria for DIC [7]. For this reason, the JSTH proposed a provisional draft of the DIC diagnostic criteria, which used the classifications of “hematopoietic disorder type” which omitted the platelet count score, “infectious type” which omitted the fibrinogen score, and “basic type” based on the underlying pathology [2, 3]. An additional point was added to the GCTs scoring system if the platelet count decreased with time, and molecular markers and the antithrombin (AT) activity were added to the new criteria. To protect against misdiagnosis, 3 points were deducted if a patient had liver failure. After the drafting of the proposed criteria [3], several evaluations were carried out to examine the issues associated with the diagnosis of the three types of DIC [8-10]. 1) What is the most useful combination for diagnosing DIC? The combination of GCTs, decreased platelet count, AT, increased soluble fibrin (SF), thrombin AT complex (TAT) or prothrombin complex F1 + 2 (F1 + 2) scores had the highest area under the curve (ARC) values and odds ratio in a analysis [8-10]. 2) Can this scoring system diagnose early-phase DIC? The JSTH diagnostic criteria could diagnose DIC several days before its onset (as defined by the JMHW criteria). 3) What score is appropriate for making a diagnosis of DIC? The ROC analysis revealed that a score of 4 points was an adequate cutoff value for hematopoietic disorder-type DIC {area under the curve (AUC) 0.979; sensitivity 97.2%; specificity 96.0%; positive predictive value (PPV) 95.4; negative predictive value (NPV) 97.6% and odd’s ratio 832} [8], while a score of 5 points (instead of the 6 points in the previous criteria) [2, 3] was suitable for the diagnosis of infectious-type DIC {AUC 0.984; sensitivity 93.7%; specificity 97.8%; positive predictive value (PPV) 98.3; negative predictive value (NPV) 91.7% and odd’s ratio 649} [9] and a score of 6 points was suitable for the diagnosis of basic-type DIC [10] {AUC 0.987; sensitivity 98.4%; specificity 94.8%; positive predictive value (PPV) 91.2; negative predictive value (NPV) 99.1% and odd’s ratio 1137}. 4) Can these diagnostic criteria predict a poor outcome? Although these diagnostic criteria can predict a poor outcome (odds ratio 2–3), there were no significant differences in the odds ratios of any of the combinations [8-11]. Thus, these diagnostic criteria have been approved as JSTH diagnostic criteria (Table 1) [12].
Table 1

JSTH’s DIC diagnostic criteria

Classification of typeBasicHematopoietic disorderInfectious
GCTsPlatelet count (×103/μl)>1200 p>1200 p
80 < − ≤ 1201 p80 < − ≤ 1201 p
50 < − ≤ 802 p50 < − ≤ 802 p
≤503 p≤503 p
≥30% decrease w/in 24 h (*1)+1 p≥30% decrease w/in 24 h (*1)+1 p
FDP(μg/ml)<100 p<100 p<100 p
10 ≤ − < 201 p10 ≤ − < 201 p10 ≤ − < 201 p
20 ≤ − < 402 p20 ≤ − < 402 p20 ≤ − < 402 p
≥403 p≥403 p≥403 p
Fibrinogen(mg/dl)>1500 p>1500 p
100 < − ≤ 1501 p100 < − ≤ 1501 p
≤1002 p≤1002 p
Prothrombin time ratio<1.250 p<1.250 p<1.250 p
1.25 ≤ − < 1.671 p1.25 ≤ − < 1.671 p1.25 ≤ − < 1.671 p
≥1.672 p≥1.672 p≥1.672 p
HMMsAntithrombin(%)>700 p>700 p>700 p
≤701 p≤701 p≤701 p
TAT, SF or F1+2 <2-fold of normal upper limit0 p<2-fold of normal upper limit0 p<2-fold of normal upper limit0 p
≥2-fold of normal upper limit1 p≥2-fold of normal upper limit1 p≥2-fold of normal upper limit1 p
Liver failure(*2)No0 pNo0 pNo0 p
Yes−3 pYes−3 pYes−3 p
DIC diagnosis≥6 p≥4 p≥5 p

Abbreviations: p points, GCT:global coagulation tests, HMMs hemostatic molecular markers

(*1): For a platelet count of >50 × 103/μL, points will be added if the time-course conditions of decrease are met (no points will be added for a platelet count of ≤50 × 103/μL). The maximum score for the platelet count is 3 points.

For institutions that do not measure FDP (institutions that measure only D-dimer), 1 point will be added if D-dimer increases ≥2-fold the normal upper limit. The upper limit of D-dimer is different among various D-dimer kits. However, in principle, FDP should also be measured and re-evaluation performed after the results are in hand. Fibrinogen levels are usually measured using thrombin time method in Japan.

DIC may be excluded in case within normal range of FDP or D-dimer.

Prothrombin time ratio: If ISI is close to 1.0, INR will also be acceptable (However, there is no evidence supporting recommendation of the use of PT-INR for diagnosis of DIC.). For determination of PT ratio, it is recommended to use normal pooled plasma.

DIC may be excluded in case with elevated prothrombin time ratio due to vitamin K deficiency.

Thrombin-antithrombin complex (TAT), soluble fibrin (SF), prothrombin fragment 1 + 2 (F1+2): For blood sampling in difficult cases and route blood sampling, false-high values may increase. Thus, in comparison with elevation of FDP and/or D-dimer, re-testing should be done if TAT and/or SF is markedly elevated. Confirmation is needed even if the results on the same day are not in time. Normal reference range is 56–213 pmol/L in F1+2, 0–3.2 μg/ml in SF and 0.3–1.5 ng/ml in TAT in Mie University Hospital.

Regardless of the presence or absence of DIC immediately after surgery, changes in DIC-like markers such as elevation of TAT, SF, FDP, or D-dimer or a decrease in AT, may be observed, and judgment should be made with care.

(*2) Liver failure: Corresponds to “a prothrombin time activity of ≤40% or an INR value of ≥1.5 due to severe liver dysfunction seen within 8 weeks of onset of initial symptoms following liver impairment that develops in a normal liver or a liver that is thought to exhibit normal liver function” (acute liver failure) or “cirrhosis with a Child-Pugh classification of B or C (≥7 points)” (chronic liver failure) that may be viral or autoimmune in origin, drug-induced, or caused by circulatory failure.”

Even when DIC is strongly suspected but these diagnostic criteria are not met, there should be no interference with anti-coagulation therapy based on the physician’s judgment, but repeated evaluation is necessary

JSTH’s DIC diagnostic criteria Abbreviations: p points, GCT:global coagulation tests, HMMs hemostatic molecular markers (*1): For a platelet count of >50 × 103/μL, points will be added if the time-course conditions of decrease are met (no points will be added for a platelet count of ≤50 × 103/μL). The maximum score for the platelet count is 3 points. For institutions that do not measure FDP (institutions that measure only D-dimer), 1 point will be added if D-dimer increases ≥2-fold the normal upper limit. The upper limit of D-dimer is different among various D-dimer kits. However, in principle, FDP should also be measured and re-evaluation performed after the results are in hand. Fibrinogen levels are usually measured using thrombin time method in Japan. DIC may be excluded in case within normal range of FDP or D-dimer. Prothrombin time ratio: If ISI is close to 1.0, INR will also be acceptable (However, there is no evidence supporting recommendation of the use of PT-INR for diagnosis of DIC.). For determination of PT ratio, it is recommended to use normal pooled plasma. DIC may be excluded in case with elevated prothrombin time ratio due to vitamin K deficiency. Thrombin-antithrombin complex (TAT), soluble fibrin (SF), prothrombin fragment 1 + 2 (F1+2): For blood sampling in difficult cases and route blood sampling, false-high values may increase. Thus, in comparison with elevation of FDP and/or D-dimer, re-testing should be done if TAT and/or SF is markedly elevated. Confirmation is needed even if the results on the same day are not in time. Normal reference range is 56–213 pmol/L in F1+2, 0–3.2 μg/ml in SF and 0.3–1.5 ng/ml in TAT in Mie University Hospital. Regardless of the presence or absence of DIC immediately after surgery, changes in DIC-like markers such as elevation of TAT, SF, FDP, or D-dimer or a decrease in AT, may be observed, and judgment should be made with care. (*2) Liver failure: Corresponds to “a prothrombin time activity of ≤40% or an INR value of ≥1.5 due to severe liver dysfunction seen within 8 weeks of onset of initial symptoms following liver impairment that develops in a normal liver or a liver that is thought to exhibit normal liver function” (acute liver failure) or “cirrhosis with a Child-Pugh classification of B or C (≥7 points)” (chronic liver failure) that may be viral or autoimmune in origin, drug-induced, or caused by circulatory failure.” Even when DIC is strongly suspected but these diagnostic criteria are not met, there should be no interference with anti-coagulation therapy based on the physician’s judgment, but repeated evaluation is necessary In conclusion, the JSTH diagnostic criteria for DIC have been revised and approved: Infectious-type DIC is now diagnosed based on a score of 5 points instead of 6 points.
  10 in total

1.  Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation.

Authors:  F B Taylor; C H Toh; W K Hoots; H Wada; M Levi
Journal:  Thromb Haemost       Date:  2001-11       Impact factor: 5.249

2.  The valuable diagnosis of DIC and pre-DIC and prediction of a poor outcome by the evaluation of diagnostic criteria for DIC in patients with hematopoietic injury established by the Japanese Society of Thrombosis and Hemostasis.

Authors:  Takumi Aota; Hideo Wada; Naoki Fujimoto; Kazushi Sugimoto; Yoshiki Yamashita; Takeshi Matsumoto; Kohshi Ohishi; Kei Suzuki; Hiroshi Imai; Kazuo Kawasugi; Seiji Madoiwa; Hidesaku Asakura; Naoyuki Katayama
Journal:  Thromb Res       Date:  2016-09-28       Impact factor: 3.944

3.  Evaluation of the Diagnostic Criteria for the Basic Type of DIC Established by the Japanese Society of Thrombosis and Hemostasis.

Authors:  Takumi Aota; Hideo Wada; Naoki Fujimoto; Yoshiki Yamashita; Takeshi Matsumoto; Kohshi Ohishi; Kei Suzuki; Hiroshi Imai; Masanobu Usui; Shuji Isaji; Toshimasa Uchiyama; Yoshinobu Seki; Naoyuki Katayama
Journal:  Clin Appl Thromb Hemost       Date:  2016-10-11       Impact factor: 2.389

4.  Efficacy and safety of anticoagulant therapy in three specific populations with sepsis: a meta-analysis of randomized controlled trials: comment.

Authors:  H Wada; T Matsumoto; T Aota; H Imai; K Suzuki; N Katayama
Journal:  J Thromb Haemost       Date:  2016-09-17       Impact factor: 5.824

5.  Criteria for diagnosis of DIC based on the analysis of clinical and laboratory findings in 345 DIC patients collected by the Research Committee on DIC in Japan.

Authors:  N Kobayashi; T Maekawa; M Takada; H Tanaka; H Gonmori
Journal:  Bibl Haematol       Date:  1983

Review 6.  Disseminated intravascular coagulation: testing and diagnosis.

Authors:  Hideo Wada; Takeshi Matsumoto; Yoshiki Yamashita; Tsuyoshi Hatada
Journal:  Clin Chim Acta       Date:  2014-04-30       Impact factor: 3.786

7.  An Evaluation of the Modified Diagnostic Criteria for DIC Established by the Japanese Society of Thrombosis and Hemostasis.

Authors:  Takumi Aota; Hideo Wada; Yoshiki Yamashita; Takeshi Matsumoto; Kohshi Ohishi; Kei Suzuki; Hiroshi Imai; Masanobu Usui; Shuji Isaji; Hidesaku Asakura; Kohji Okamoto; Naoyuki Katayama
Journal:  Clin Appl Thromb Hemost       Date:  2016-06-14       Impact factor: 2.389

8.  Prospective evaluation of three different diagnostic criteria for disseminated intravascular coagulation.

Authors:  Takemitsu Takemitsu; Hideo Wada; Tsuyoshi Hatada; Yukinari Ohmori; Ken Ishikura; Taichi Takeda; Takashi Sugiyama; Norikazu Yamada; Kazuo Maruyama; Naoyuki Katayama; Shiji Isaji; Hideto Shimpo; Masato Kusunoki; Tsutomu Nobori
Journal:  Thromb Haemost       Date:  2010-10-12       Impact factor: 5.249

9.  Natural history of disseminated intravascular coagulation diagnosed based on the newly established diagnostic criteria for critically ill patients: results of a multicenter, prospective survey.

Authors:  Satoshi Gando; Daizoh Saitoh; Hiroshi Ogura; Toshihiko Mayumi; Kazuhide Koseki; Toshiaki Ikeda; Hiroyasu Ishikura; Toshiaki Iba; Masashi Ueyama; Yutaka Eguchi; Yasuhiro Ohtomo; Kohji Okamoto; Shigeki Kushimoto; Shigeatsu Endo; Shuji Shimazaki
Journal:  Crit Care Med       Date:  2008-01       Impact factor: 7.598

Review 10.  Proposal for new diagnostic criteria for DIC from the Japanese Society on Thrombosis and Hemostasis.

Authors:  Hidesaku Asakura; Hoyu Takahashi; Toshimasa Uchiyama; Yutaka Eguchi; Kohji Okamoto; Kazuo Kawasugi; Seiji Madoiwa; Hideo Wada
Journal:  Thromb J       Date:  2016-09-28
  10 in total
  9 in total

1.  Underlying Disorders, Clinical Phenotypes, and Treatment Diversity among Patients with Disseminated Intravascular Coagulation.

Authors:  Hiroyuki Ohbe; Kazuma Yamakawa; Kohei Taniguchi; Kojiro Morita; Hiroki Matsui; Kiyohide Fushimi; Hideo Yasunaga
Journal:  JMA J       Date:  2020-09-23

2.  Effect of disseminated intravascular coagulation on donation after citizens' death donor kidneys.

Authors:  Lu Xu; Wei Yin; Guanghui Li; Jiali Fang; Lei Zhang; Luhao Liu; Yunyi Xiong; Jialin Wu; Guanghui Pan; Junjie Ma; Zheng Chen
Journal:  Transl Androl Urol       Date:  2021-03

3.  Disseminated intravascular coagulation diagnosis: Positive predictive value of the ISTH score in a Danish population.

Authors:  Julie Brogaard Larsen; Mathies Appel Aggerbeck; Asger Granfeldt; Morten Schmidt; Anne-Mette Hvas; Kasper Adelborg
Journal:  Res Pract Thromb Haemost       Date:  2021-12-09

4.  Proposal of Quick Diagnostic Criteria for Disseminated Intravascular Coagulation.

Authors:  Hideo Wada; Akitaka Yamamoto; Masaki Tomida; Yuhuko Ichikawa; Minoru Ezaki; Jun Masuda; Masamichi Yoshida; Shunsuke Fukui; Isao Moritani; Hidekazu Inoue; Katsuya Shiraki; Kei Suzuki; Hiroshi Imai; Motomu Shimaoka; Hideto Shimpo
Journal:  J Clin Med       Date:  2022-02-16       Impact factor: 4.241

Review 5.  Differences and similarities between disseminated intravascular coagulation and thrombotic microangiopathy.

Authors:  Hideo Wada; Takeshi Matsumoto; Kei Suzuki; Hiroshi Imai; Naoyuki Katayama; Toshiaki Iba; Masanori Matsumoto
Journal:  Thromb J       Date:  2018-07-11

6.  Severe Antithrombin Deficiency May be Associated With a High Risk of Pathological Progression of DIC With Suppressed Fibrinolysis.

Authors:  Hideo Wada; Goichi Honda; Noriaki Kawano; Toshimasa Uchiyama; Kazuo Kawasugi; Seiji Madoiwa; Naoki Takezako; Kei Suzuki; Yoshinobu Seki; Takayuki Ikezoe; Toshiaki Iba; Kohji Okamoto
Journal:  Clin Appl Thromb Hemost       Date:  2020 Jan-Dec       Impact factor: 2.389

7.  Serum histone H3 levels and platelet counts are potential markers for coagulopathy with high risk of death in septic patients: a single-center observational study.

Authors:  Takashi Ito; Takaaki Totoki; Yayoi Yokoyama; Tomotsugu Yasuda; Hiroaki Furubeppu; Shingo Yamada; Ikuro Maruyama; Yasuyuki Kakihana
Journal:  J Intensive Care       Date:  2019-12-26

Review 8.  Recent advances in the research and management of sepsis-associated DIC.

Authors:  Toshiaki Iba; Jean Marie Connors; Isao Nagaoka; Jerrold H Levy
Journal:  Int J Hematol       Date:  2021-01-02       Impact factor: 2.490

9.  Diversity of disseminated intravascular coagulation and selection of appropriate treatments.

Authors:  Hidesaku Asakura
Journal:  Int J Hematol       Date:  2020-11-07       Impact factor: 2.319

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.